10x Genomics, Inc.: Form 10-K for the period ended Dec 31, 2022
Filed with the SEC on Feb 16, 2023 and accepted by EDGAR at Feb 16, 2023, 16:48 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2022-01-01 to 2022-12-31 | $516.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2022-01-01 to 2022-12-31 | $120.4m | us-gaap:CostOfRevenue |
| Gross profit | 12 months2022-01-01 to 2022-12-31 | $396.0m | us-gaap:GrossProfit |
| Selling, general and administrative | 12 months2022-01-01 to 2022-12-31 | $298.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2022-01-01 to 2022-12-31 | −$167.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2022-01-01 to 2022-12-31 | $476.0k | us-gaap:InterestExpense |
| Income tax | 12 months2022-01-01 to 2022-12-31 | $4.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2022-01-01 to 2022-12-31 | −$166.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2022-01-01 to 2022-12-31 | −$1.46 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2022-01-01 to 2022-12-31 | −$1.46 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2022-01-01 to 2022-12-31 | 113,858,684 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2022-01-01 to 2022-12-31 | −$33.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2022-01-01 to 2022-12-31 | $131.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-12-31 | $219.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-12-31 | $635.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-12-31 | $1.03bn | us-gaap:Assets |
| Current liabilities | At period end2022-12-31 | $131.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-12-31 | $223.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-12-31 | $805.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001770787-23-000012. Last ingested by Listed: Nov 6, 2026, 17:47 ET. Listed shows no prices and gives no investment advice.